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Objectives This study investigated the influence of intracoronary enalaprilat on coronary microvascular function and peri-
procedural outcome measures in patients with stable angina undergoing percutaneous coronary intervention (PCI).
Background Intracoronary angiotensin-converting enzyme inhibitors have been shown to relieve myocardial ischemia in sta-
ble patients and to improve epicardial flow in patients with ST-segment elevation myocardial infarction. Yet, it is
still unclear whether these effects are mediated by a modulation of the coronary microcirculation.
Methods We randomly assigned 40 patients to receive either an intracoronary bolus of enalaprilat (50 g) or placebo be-
fore elective PCI. The index of microvascular resistance was measured at baseline, 10 minutes after study drug
administration, and after PCI. High-sensitivity cardiac troponin T was measured as a marker of myocardial injury.
Results Infusion of enalaprilat resulted in a significant reduction in index of microvascular resistance (27  11 at base-
line vs. 19  9 after drug vs. 15  8 after PCI), whereas a significant post-procedural increase in index of micro-
vascular resistance levels was observed in the placebo group (24  15 at baseline vs. 24  15 after drug vs.
33  19 after PCI). Index of microvascular resistance levels after PCI were significantly lower in the enalaprilat
group (p  0.001). Patients pre-treated with enalaprilat also showed lower peak values (mean: 21.7 ng/ml,
range: 8.2 to 34.8 ng/ml vs. mean: 32.3 ng/ml, range: 12.6 to 65.2 ng/ml, p  0.048) and peri-procedural in-
creases of high-sensitivity cardiac troponin T (mean: 9.9 ng/ml, range: 2.7 to 19.0 ng/ml vs. mean: 26.6 ng/ml,
range: 6.3 to 60.5 ng/ml, p  0.025).
Conclusions Intracoronary enalaprilat improves coronary microvascular function and protects myocardium from procedure-
related injury in patients with coronary artery disease undergoing PCI. Larger studies are warranted to investi-
gate whether these effects of enalaprilat could result into a significant clinical benefit. (J Am Coll Cardiol
2013;61:615–21) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.025Angiotensin-converting enzyme (ACE) inhibitors improve
clinical outcomes in patients with coronary artery disease
(1–4). Beyond the long-term protective effect of the oral
treatment, intracoronary administration of ACE inhibitors
may be beneficial in patients undergoing percutaneous
coronary intervention (PCI). Pretreatment with intracoro-
nary enalaprilat of patients with stable coronary artery
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2012, accepted November 12, 2012.disease relieved myocardial ischemia during PCI, as assessed
by intracoronary electrocardiogram and chest pain score (5).
Moreover, in patients undergoing primary PCI for ST-
segment elevation myocardial infarction, enalaprilat injec-
tion in the infarct-related artery reduces the adhesion of
inflammatory cells and improves epicardial flow (6). Possi-
ble mechanisms underlying these protective effects include
an improvement of the endothelium-dependent epicardial
coronary vasodilation mediated by an increase in endoge-
nous bradykinin activity (7). In addition, preliminary find-
ings from experimental models suggest that enalaprilat also
may lead to an improvement of coronary blood flow and
coronary flow reserve (CFR) (8). Yet, it is still unclear
whether this latter effect is exerted mainly at the level of the
coronary microcirculation.
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The ProMicro Study February 12, 2013:615–21In the present study, we inves-
tigated whether enalaprilat im-
proves coronary microvascular
function, as assessed with the in-
dex of microvascular resistance
(IMR), and we assess its relative
impact on peri-procedural out-
comes in patients undergoing
elective PCI.
Methods
This was a prospective, random-
ized, double-blind, controlled
study carried out at the Cardiovas-
cular Center Aalst OLV Clinic,
Aalst, Belgium, between February
and September 2011.
Patient population. We enrolled 40 patients with stable
coronary disease referred for elective PCI of an isolated,
functionally significant (fractional flow reserve [FFR]:
0.80) lesion located in the proximal two-thirds of a major
coronary artery. Patients were excluded in the presence of
the following conditions: treatment with oral ACE inhibi-
tors in the previous 15 days, previous myocardial infarction,
left ventricle ejection fraction less than 50%, left ventricle
wall-motion abnormalities, left ventricular hypertrophy, in-
stent restenosis, bifurcation with side branch of more than 2
mm, ostial lesion, and contraindications to adenosine. The
study protocol was approved by the institutional ethics
committee, and patients gave informed consent for partic-
ipation and data collection.
Adjunctive medications. All patients were administered a
loading dose of 600 mg clopidogrel and 500 mg aspirin the
day before the procedure. During catheterization, all pa-
tients received a weight-adjusted intravenous heparin bolus
(100 IU/kg) to maintain an activated clotting time of
between 250 and 300s.
Study protocol. Patients were assigned randomly to receive
either an intracoronary bolus of enalaprilat or placebo before
PCI. Assignment to 1 of the 2 treatments was determined
by a computer-based randomization system, and random-
ization assignment for each patient was kept in a sealed
envelope. Enalaprilat 50 g in 5 ml NaCl 0.9% was
administrated to the study patients (9); 5 ml NaCl 0.9% was
administrated to the placebo patients. Both the patient and
the catheterization laboratory team (operator and scrub
nurse) were blinded to the assigned treatment. An indepen-
dent study nurse not involved in the procedure was respon-
sible of opening the sealed envelope and preparing the
solution of enalaprilat (active drug) or placebo (pure saline)
to be administered according to treatment allocation. Enal-
aprilat or placebo was infused in the target coronary artery
through the guiding catheter over a 2-min period, followed
by a 10-ml 0.9% NaCl solution flush. The dosage of
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
CFR  coronary flow
reserve
FFR  fractional flow
reserve
hs-cTnT  high-sensitivity
cardiac troponin T
IMR  index of
microvascular resistance
PCI  percutaneous
coronary intervention
PMI  periprocedural
myocardial infarctionenalaprilat was chosen on the basis of previous studies (9). pCoronary physiological indexes (CFR, IMR, and FFR)
were measured in each patient at baseline (before study drug
administration), 10 min after study drug administration,
and after PCI, as previously described (10–18). Briefly, an
intracoronary pressure and temperature sensor-tipped
guidewire (PressureWire Certus, RADI, St. Jude Medical,
Uppsala, Sweden) was used to measure distal coronary
pressure and to derive thermodilution curves. Thermodilu-
tion curves were obtained (in triplicate) from a hand-held,
3-ml rapid (0.25 s) injection of room temperature saline at
baseline and during maximal hyperemia, which was
achieved by infusion of 140 g/kg per minute of adenosine
via the femoral vein. Mean transit time (Tmn) at baseline
nd during maximal hyperemia was derived from thermodi-
ution curves. Simultaneous recordings of mean aortic pres-
ure (guiding catheter, Pa) and mean distal coronary pres-
sure (distal pressure sensor, Pd) also were obtained at
baseline and during maximal hyperemia. The CFR was
calculated from the ratio of hyperemic to baseline Tmn. The
MR was calculated using the following equation: IMR 
a Tmn [(Pd Pw) / (Pa Pw)], where Pw is the coronary
wedge pressure. Pw was measured as the distal coronary
ressure (from the distal pressure and temperature sensor)
uring complete balloon occlusion of the vessel obtained
uring PCI. The FFR was calculated from the ratio of distal
o proximal pressures at maximal hyperemia. The PCI
rocedures were performed by standard technique. In all
ases, balloon pre-dilatation was performed before stent
mplantation.
eri-procedural myocardial necrosis. High-sensitivity
ardiac troponin T (hs-cTnT) (Roche Diagnostics, Mann-
eim, Germany) was determined in blood samples taken
efore and 8 and 24 h after intervention. Peri-procedural
yocardial infarction (PMI) was defined as a post-
rocedural increase in hs-cTnT more than 3 times the 99th
ercentile of the upper reference limit (i.e., 14 ng/ml) for
atients with baseline negative myocardial necrosis markers,
onsistent with the joint European Society of Cardiology/
merican College of Cardiology Foundation/American
eart Association/World Heart Federation task force con-
ensus statement on the redefinition of myocardial infarc-
ion for clinical trials on coronary intervention (19). In
atients with increased baseline levels of hs-cTnT, a subse-
uent increase of more than 50% of the baseline value
ulfilled the criteria for PMI (20).
tatistical analysis. At the time the ProMicro (EnalaPrilat
o Reduce MICROvascular Damage During Percutaneous
oronary Intervention) (ProMicro) trial was conceived, no
tudies were available specifically reporting on the impact of
nalaprilat on microvascular function. However, we based
ur sample size calculation on our previous studies showing
hat a strategy of direct stenting resulted in a significant
mpact on microvascular function with a 45% reduction in
MR after PCI compared with conventional balloon angio-
lasty followed by stent implantation (as performed in the
resent study) (21,22). Assuming a 33% reduction in IMR
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February 12, 2013:615–21 The ProMicro Studyafter PCI in the enalaprilat group, a total of at least 17
patients per group was needed to achieve an 80% power at
a 2-sided alpha of 0.05 to detect the expected difference.
Therefore, we aimed at enrolling a total of 40 patients (20
per group). Continuous variables are expressed as mean 
SD or as median (interquartile range), as appropriate.
Categorical variables are reported as frequencies and per-
centages. Normal distribution was tested with the
D’Agostino-Pearson omnibus K2 test. Comparisons be-
tween continuous variables were performed using the Stu-
dent t test or Mann-Whitney U test. These tests were
corrected for repeated measures where appropriate. The
IMR at baseline, after drug administration, and after PCI
was compared with an analysis of variance (ANOVA) for
repeated measures or with the Friedman test, as appropriate.
Comparisons between categorical variables were evaluated
using the Fisher exact test or the Pearson chi-square test, as
appropriate. Correlations between continuous variables
were assessed using the Spearman rank correlation test. A
2-way ANOVA for repeated measures was used to detect
changes in IMR levels over time in the 2 study groups.
Statistical analyses was performed using STATA/IC soft-
ware version 10 (STATA Corp., College Station, Texas)
and p values 0.05 (2-tailed) were considered significant.
Results
Patient population. A total of 40 patients were enrolled in
this study: 20 randomized to the enalaprilat group and 20
randomized to the placebo group. Baseline clinical and
procedural characteristics are shown in Tables 1 and 2,
respectively. No significant differences were found between
the 2 study groups for any of the variables reported.
Measurements of coronary physiological indices. Mea-
surements of the physiologic indices in the 2 groups at the
3 time points are reported in Figure 1 and Table 3. In the
Clinical CharacteristicsTable 1 Clinical Characteristics
Enalaprilat
(n  20)
Placebo
(n  20) p Value
Age (yrs) 64 10 64 11 0.926
Male 14 (70) 18 (90) 0.235
BMI (kg/m2) 27.9 3.6 27.1 4.0 0.593
Hypertension 14 (70) 11 (55) 0.327
Diabetes mellitus 5 (25) 3 (15) 0.695
Dyslipidemia 16 (80) 14 (70) 0.716
Smoking habit 7 (35) 5 (25) 0.731
Previous PCI 6 (30) 4 (20) 0.716
LVEF (%) 61 9 63 9 0.739
Serum creatinine (mg) 0.96 0.25 0.97 0.13 0.891
C reactive protein (mg/l) 3.5 2.6 2.1 1.3 0.317
Beta blockers 13 (65) 10 (50) 0.337
Calcium channel blockers 5 (25) 5 (25) 1.000
Statins 18 (90) 17 (85) 1.000
Value are mean  SD or n (%).
BMI  body mass index; LVEF  left ventricular ejection fraction; PCI  percutaneous coronary
ntervention.enalaprilat group, a significant change in IMR (p  0.0001,
ANOVA) was observed after drug administration and after
PCI, whereas no significant variations were observed in the
placebo group (p  0.058, Friedman test).
At baseline, FFR, CFR, and IMR were similar in 2 study
groups. After drug administration, a significant reduction in
IMR was detected in the enalaprilat group (27  11 at
baseline vs. 19  9 after drug administration, p  0.001),
whereas no significant variations were observed in the
placebo group (24  15 at baseline vs. 24  15 after drug
administration, p  0.899). Likewise, CFR increased sig-
nificantly in the enalaprilat group (2.2  1.4 at baseline vs.
2.7  1.3 after drug administration, p  0.004), whereas it
did not change significantly in the placebo group (2.4  0.9
at baseline vs. 2.4 1.0 after drug administration, p 0.870).
The FFR decreased significantly after drug administration
in the enalaprilat group (p  0.023 after drug administra-
tion vs. baseline), but did not change in the placebo group
(p  0.527 after drug administration vs. baseline). After
PCI, procedural success was achieved in all patients: FFR
values increased to more than the ischemic threshold of 0.80
(enalaprilat: p  0.001 vs. baseline, placebo: p  0.001 vs.
baseline), with no significant differences in FFR values after
PCI between the 2 study groups (Table 3). However,
patients in the enalaprilat group showed significantly lower
IMR values after PCI compared with those who received
placebo (15  8 vs. 33  19, p  0.001) (Table 3). In
particular, although in the enalaprilat group a further
reduction in IMR was observed (p 0.001 vs. baseline, p
0.027 vs. after drug administration), a significant increase in
IMR values was detected in the placebo group after PCI
(p  0.017 vs. baseline, p  0.018 vs. after drug adminis-
tration) (Fig. 1). Using a 2-way ANOVA, a significant
interaction between study group and IMR at the 3 study
time points (baseline, after drug administration, and after
PCI) was found in determining IMR values (p  0.003).
Consistently, in the enalaprilat group, a significant increase
in CFR after PCI was observed (p 0.001 vs. baseline, p
Procedural CharacteristicsTable 2 Procedural Characteristics
Enalaprilat
(n  20)
Placebo
(n  20) p Value
Target vessel 0.507
LAD 11 (55) 14 (70)
LCx 3 (15) 3 (15)
RCA 6 (30) 3 (15)
Percent stenosis (%) 65 11 64 13 0.964
Number of stents 1.3 0.6 1.2 0.5 0.545
Drug-eluting stent, 11 (55) 10 (50) 0.752
Stent diameter (mm) 3.08 0.44 3.07 0.34 0.924
Stent length (mm) 24 7 21 7 0.235
Maximal inflation pressure (mm Hg) 15 2 13 5 0.153
Post-dilatation 14 (70) 13 (65) 0.736
Values are n (%) or mean  SD.
LAD  left anterior descending artery; LCx  left circumflex artery; RCA  right coronary artery.0.008 vs. after drug administration), whereas in the placebo
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The ProMicro Study February 12, 2013:615–21group, CFR did not change significantly (p  0.352 vs.
baseline, p  0.287 vs. after drug administration). A trend
toward higher CFR values was observed in the enalaprilat
group as compared with the placebo group (3.6  1.8 vs.
2.7  1.2, p  0.100).
Peri-procedural myocardial necrosis. Baseline levels of
hs-cTnT were similar in the 2 study groups (mean: 7.0
ng/ml, range: 3.0 to 15.6 ng/ml in the enalaprilat group vs.
mean: 4.1 ng/ml, range: 3.0 to 8.1 ng/ml in the placebo
group, p  0.259). The peri-procedural increase in hs-
cTnT was significantly lower in the enalaprilat group
Figure 1 Variations of Microvascular Function During Percutan
The index of microvascular resistance (IMR) at baseline, after drug administration
(Left) Patients treated with enalaprilat. (Right) Patients treated with placebo. Box
(median). Whiskers show the highest and the lowest values. ANOVA  analysis o
Physiological MeasurementsTable 3 Physiological Measurements
Enalaprilat
(n20)
Placebo
(n20) p value
Baseline
SBP 126 16 130 23 0.412
DBP 66 7 69 11 0.321
HR 65 9 67 10 0.522
FFR 0.70 0.13 0.71 0.14 0.944
IMR 27 11 24 15 0.513
CFR 2.2 1.4 2.4 0.9 0.534
After drug administration
SPB 127 20 129 23 0.783
DBP 66 8 68 12 0.436
HR 66 9 68 10 0.500
FFR 0.69 0.13 0.71 0.14 0.749
IMR 19 9 24 15 0.270
CFR 2.7 1.3 2.4 1.0 0.550
After PCI
SBP 133 21 133 24 0.989
DBP 68 9 70 13 0.534
HR 65 8 67 10 0.472
FFR 0.89 0.06 0.89 0.07 0.652
IMR 15 8 33 19 0.001
CFR 3.6 1.8 2.7 1.2 0.100
Values are mean  SD.d
CFR  coronary flow reserve; DBP  diastolic blood pressure; FFR  fractional flow reserve;
HR  heart rate; IMR  index of microvascular resistance; SBP  systolic blood pressure.compared with the placebo group (mean: 9.9 ng/ml, range:
2.7 to 19.0 ng/ml vs. mean: 26.6 ng/ml, range: 6.3 to 60.5
ng/ml, p  0.025) (Fig. 2A). A total of 12 (30%) patients
demonstrated PMI; of these, 3 (15%) were in the enalaprilat
group and 9 (45%) were in the placebo group (p  0.034)
(Fig. 2B).
Correlation between IMR and myocardial necrosis. A
significant correlation was found between IMR after PCI
and peri-procedural hs-cTnT increase, both in patients in
the enalaprilat group (rho  0.463, p  0.040) and in those
f the placebo group (rho  0.457, p  0.045) (Fig. 3).
urthermore, patients who had PMI showed significantly
igher IMR values after PCI compared with those who did
ot have PMI (33  22 vs. 20  13, p  0.023) (Fig. 4).
iscussion
n this randomized, controlled, double-blind study con-
ucted in patients with stable coronary artery disease, we
ound that intracoronary enalaprilat improves coronary mi-
rovascular function and prevents the occurrence of micro-
ascular impairment related to PCI. This beneficial effect of
nalaprilat on the microcirculation was associated with a
educed PCI-related myocardial injury.
In patients with coronary atherosclerotic disease, ACE
nhibitors have been associated with a significant reduction
n mortality and adverse cardiovascular events (1–4). One of
he proposed mechanisms underlying this beneficial effect
as attributed to an improvement in endothelial function
23,24). In chronically instrumented dogs with dilated
ardiomyopathy, enalaprilat improved transmural myocar-
ial perfusion and restored impaired coronary flow (8). In
atients with endothelial dysfunction, the improvement of
rachial flow-mediated dilation with ACE inhibitors was by
ar superior to that achieved by other antihypertensive drugs
25,26). This effect also has been observed acutely and
ocally in patients with mild coronary atherosclerosis, as
Coronary Intervention
r enalaprilat or placebo), and after percutaneous coronary intervention (PCI).
end from the 25th to the 75th percentile, with a line at the 50th percentile
ce.eous
(eithe
es ext
f varianemonstrated by the selective improvement of the
p
H
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February 12, 2013:615–21 The ProMicro Studyendothelium-dependent epicardial vasomotion induced by
intracoronary enalaprilat, an effect mediated at least in part
through an increase in endogenous bradykinin activity (7).
In addition, intracoronary enalaprilat in patients with
chronic stable angina undergoing PCI attenuated chest pain
and ST-segment changes during balloon inflation (5).
Moreover, a significant increase in coronary blood flow was
observed in 6 patients, as measured with an intracoronary
Doppler wire after enalaprilat infusion. Of note, this effect
was not accompanied by a significant epicardial coronary
vasodilation, suggesting that mostly coronary microvascula-
ture could be involved in determining flow augmentation
(5). In ST-segment elevation myocardial infarction patients
undergoing primary PCI, intracoronary enalaprilat after
reopening the infarct-related artery improved coronary
blood flow, as assessed by corrected thrombolysis in myo-
cardial infarction frame counts, and prevented the increase
in L-selectin, P-selectin, and endothelin-1 observed during
reperfusion (6).
Our findings confirmed and further extended the avail-
able evidence. We confirmed that intracoronary enalaprilat
significantly increased CFR (from 2.2  1.4 to 2.7  1.3,
 0.004), as measured with intracoronary thermodilution.
ad we based our indication for PCI on a CFR cutoff for
Figure 2 Peri-procedural Myocardial Necrosis
(A) Peri-procedural increase in high-sensitivity cardiac troponin T (hs-cTnT) and (B)
Figure 3 Microvascular Function and Peri-procedural Myocardia
Correlation between index of microvascular resistance (IMR) after PCI and peri-profunctional significance of coronary stenosis (27), this might
have had an impact on clinical decision making. According
to published guidelines (28), we based our indication for
PCI on symptoms, noninvasive functional tests available,
and positive value of FFR. Unlike FFR, which is a specific
index of the epicardial coronary stenosis severity, CFR does
not enable distinguishing between the contribution of the
epicardial and microvascular component to the flow reduc-
tion. Whether this increase in CFR could be sustained and
is sufficient to relieve completely patient’s symptoms, myo-
cardial ischemia, or both is unknown, although this seems
unlikely because FFR values showed only minor changes
(from 0.70 013 to 0.69 0.13, p 0.023) that remained
always less than the ischemic threshold of 0.80.
We extended the available data by demonstrating that
this effect mainly was the result of an improvement in
microvascular function, as assessed by the IMR, specifically
evaluating the presence of microvascular dysfunction (12–
15). We also found that microvascular dysfunction related
to PCI was prevented by the administration of enalaprilat.
In fact, IMR increased after PCI in the placebo group,
whereas it was found to be decreased significantly in the
enalaprilat group, therefore suggesting a protective role of
ACE inhibition on coronary microvasculature during PCI.
nce of peri-procedural myocardial infarction (PMI) in the 2 study groups.
crosis
l increase in hs-cTnT in the 2 study groups. Abbreviations as in Figures 1 and 2.incidel Ne
cedura
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The ProMicro Study February 12, 2013:615–21Of note, microvascular resistance in the enalaprilat group
was found to be even lower after PCI compared with 10 min
after drug administration. We can speculate that the effect
of enalaprilat on IMR did not reach the peak 10 min after
drug infusion, but was prolonged over time. Alternatively,
we cannot exclude an interaction between enalaprilat and
PCI effects on microvascular resistance.
We cannot provide a mechanistic explanation for these
results, but we can speculate, based on previous data (6),
that the beneficial effect of enalaprilat on coronary micro-
circulation could be related to the reduction of neurohor-
monal and inflammatory markers, such as endothelin-1 and
norepinephrine, and the increased availability of bradykinin
and nitric oxide induced by this drug. Moreover, bradykinin
is a well-known inducer of cardiac preconditioning; there-
fore, we also may be able to attribute to enalaprilat a
protective effect from PCI-related myocardial damage that
is mediated by the potentiation of bradykinin.
In our patients, we noted a slight, albeit significant, FFR
reduction after enalaprilat administration (from 0.70 0.13
to 0.69  0.13, p  0.023). Similarly to other pharmaco-
logic agents (i.e., alpha-blockers) (29,30), this may be
explained by the ability of enalaprilat to vasodilate and
unmask some residual microvascular resistance. Yet, this did
not have any clinical impact in our study because all patients
recruited had a significant FFR of less than 0.80 and
therefore already were candidates for percutaneous coronary
revascularization. Whether this drug always should be
administrated to all patients undergoing FFR assessment,
especially to those close to threshold value for functional
significance (i.e., an FFR value of 0.80), is unknown and
goes beyond the scope of our study.
In placebo patients, despite an effective PCI, only a trend
toward an increase in CFR after PCI was observed. This is
explained partly by the limited sample size and partly by the
fact that CFR accounts for changes in both epicardial and
microvascular resistance. However, FFR accounts for
changes in flow of the epicardial coronary artery and can be
Figure 4 Microvascular Function and PMI
IMR after PCI in patients with and
without PMI. Abbreviations as in Figures 1 and 2.considered as an index of epicardial coronary resistance,whereas IMR accounts for changes in microvascular resis-
tance. In placebo patients: 1) there are no changes in epicardial
resistance (FFR) after drug administration, whereas a signifi-
cant reduction of epicardial resistance occurs after PCI; 2) no
significant changes are observed in microvascular resistance
(IMR) after drug administration, whereas a moderately in-
crease occurs after PCI; and 3) consistently with changes
occurring in both epicardial and microvascular resistance,
CFR does not change after drug administration, whereas
only a slight increase, although not statistically significant,
occurs after PCI.
This beneficial effect of enalaprilat on the microcircula-
tion translated into a reduced PCI-related myocardial in-
jury. In fact, patients pretreated with enalaprilat showed a
significantly lower post-procedural hs-cTnT release as com-
pared with patients receiving placebo. The observation of a
moderate correlation between IMR after PCI and post-
procedural hs-cTnT level suggests that the myocardial
injury that occurs at the time of PCI is reflected by an
immediate increase in IMR and a subsequent increase in
hs-cTnT. This is in line with our previous findings dem-
onstrating, in stable patients undergoing PCI, a correlation
between post-procedural troponin T elevation and IMR
values obtained in patients with conventional balloon dila-
tation followed by stent implantation versus a direct stenting
technique (21).
Our findings may be clinically relevant if considering that
even small elevations of troponin T after PCI have been
associated with subsequent adverse cardiovascular events
(31,32). Even if the issue of peri-procedural myocardial
leakage is being reappraised (33), strategies aiming at
reducing myocardial damage in the context of coronary
intervention should be welcomed in patients undergoing
coronary revascularization. In this perspective, pre-
treatment with enalaprilat could be considered as an adjunc-
tive treatment in patients with stable coronary artery disease
undergoing PCI.
Study limitations. The investigators were not blinded to
the IMR results. We measured IMR only once after PCI,
immediately after the end of the procedure; therefore,
potential further variations in microvascular function could
not be detected.
Only a low dose of enalaprilat was used in the present
study. Therefore, whether higher doses could result in an
even larger improvement in microvascular function could
not be investigated. In addition, enalaprilat was adminis-
trated selectively through the guiding catheter into the
ostium of the left or right coronary artery. In most of the
cases, the study vessel was the left coronary artery (either
the left anterior descending or the left circumflex artery).
Therefore, we cannot exclude that an even more pro-
nounced effect of enalaprilat on the microcirculation could
have been unmasked, had the injection been performed
subselectively, that is, directly into a study vessel (that is, left
anterior descending or left circumflex artery).
621JACC Vol. 61, No. 6, 2013 Mangiacapra et al.
February 12, 2013:615–21 The ProMicro StudyThe sample size of this study was relatively small.
Although no significant differences were detected in base-
line characteristics, potential unbalance between the 2 study
groups is not to be excluded entirely.
Conclusions
This randomized, controlled, double-blind study showed
for the first time that intracoronary enalaprilat is able to
improve coronary microvascular function and to protect
myocardium from procedure-related injury in patients with
coronary artery disease undergoing PCI. Further larger
studies with long-term follow-up are warranted to investi-
gate whether these effects of enalaprilat could result in a
significant clinical benefit.
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